Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy.

First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol (2010) 1.59

Malignant peripheral nerve sheath tumors. Oncologist (2014) 1.23

Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol (2005) 0.86

Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports. Cases J (2009) 0.77

MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene (2003) 7.90

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood (2002) 4.35

Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood (2009) 3.69

Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol (2005) 3.29

Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology (2002) 2.92

The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol (2011) 2.79

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood (2004) 2.77

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet (2010) 2.62

Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood (2009) 2.54

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol (2008) 2.54

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44

Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell (2009) 2.39

Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol (2005) 2.36

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood (2012) 2.27

Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol (2006) 2.22

BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood (2010) 2.17

Postoperative complications do not affect long-term outcome in esophageal cancer patients. World J Surg (2014) 2.16

Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol (2004) 2.11

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09

Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol (2009) 2.06

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol (2008) 2.01

Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur Radiol (2004) 2.01

Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood (2007) 1.99

Endoscopic retrograde cholangiopancreatography, intraductal ultrasonography, and magnetic resonance cholangiopancreatography in bile duct strictures: a prospective comparison of imaging diagnostics with histopathological correlation. Am J Gastroenterol (2004) 1.96

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol (2012) 1.91

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res (2003) 1.87

The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood (2007) 1.84

Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood (2007) 1.81

Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol (2003) 1.78

An intravital model to monitor steps of metastatic tumor cell adhesion within the hepatic microcirculation. J Gastrointest Surg (2003) 1.75

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med (2002) 1.75

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol (2009) 1.73

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood (2012) 1.73

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood (2011) 1.73

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood (2005) 1.69

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood (2002) 1.68

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood (2002) 1.68

Effect of pyloric drainage procedures on gastric passage and bile reflux after esophagectomy with gastric conduit reconstruction. Langenbecks Arch Surg (2007) 1.67

Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica (2006) 1.64

A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood (2012) 1.64

High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60

Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol (2005) 1.59

Single-lung ventilation for pulmonary lobe resection in a newborn. Anesth Analg (2005) 1.55

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res (2005) 1.51

Impact of failed allograft nephrectomy on initial function and graft survival after kidney retransplantation. Transpl Int (2010) 1.51

EP300--a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. Int J Cancer (2010) 1.51

High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res (2004) 1.50

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol (2009) 1.48

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46

Cryopreservation of sperm from adolescents and adults with malignancies. J Androl (2004) 1.46

Effective prevention of adhesions with hyaluronate. Arch Surg (2002) 1.45

Exocrine drainage into the duodenum: a novel technique for pancreas transplantation. Transpl Int (2007) 1.44

The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol (2004) 1.43

Treatment of thoracic esophageal anastomotic leaks and esophageal perforations with endoluminal stents: efficacy and current limitations. J Gastrointest Surg (2008) 1.42

S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res (2004) 1.41

Ultrasonic technology: a new treatment option for anal condylomata acuminata. Dis Colon Rectum (2008) 1.39

Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol (2009) 1.38

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33

Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest (2002) 1.33

Laparoscopic simulation training: Testing for skill acquisition and retention. Surgery (2012) 1.32

Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol (2005) 1.30

Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res (2004) 1.30

Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood (2007) 1.28

Workflow to improve patient recruitment for clinical trials within hospital information systems - a case-study. Trials (2008) 1.27

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol (2012) 1.27

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood (2003) 1.23

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood (2012) 1.22

Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol (2007) 1.22

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood (2011) 1.22

Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res (2005) 1.22

Endoscopic closure of postoperative gastrointestinal leakages and fistulas with the Over-the-Scope Clip (OTSC). J Gastrointest Surg (2013) 1.22

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol (2003) 1.18